Publicacións (20) Publicacións de Francisco Javier Afonso Afonso

2022

  1. FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities

    Clinical Drug Investigation, Vol. 42, Núm. 11, pp. 949-964

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

2020

  1. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2019

  1. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

  2. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy

    Translational Lung Cancer Research, Vol. 8, Núm. 6, pp. 1078-1085

2018

  1. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1467-1473

  2. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2016

  1. EGFR testing and clinical management of advanced NSCLC: A galician lung cancer group study (GGCP 048-10)

    Cancer Management and Research, Vol. 8, pp. 11-20

  2. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia)

    Oncology Letters, Vol. 12, Núm. 2, pp. 1403-1407

  3. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

  4. Prostate cancer perspectives after chaarted: Optimizing treatment sequence

    Critical Reviews in Oncology/Hematology, Vol. 107, pp. 119-127

2015

  1. Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor

    Cancer Treatment Reviews, Vol. 41, Núm. 3, pp. 247-253

  2. Radium-223 dichloride: A new paradigm in the treatment of prostate cancer

    Expert Review of Anticancer Therapy, Vol. 15, Núm. 3, pp. 339-348

2014

  1. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology

  3. Tumor Inflamatorio Miofibroblástico Exofítico Del Estómago Con Hemoperitoneo Espontáneo. Presentación atípica de un tumor infrecuente

    Revista Venezolana de Oncologia, Vol. 25, Núm. 4, pp. 255-259

2011

  1. Molecular basis of hypertension side effects induced by sunitinib

    Anti-Cancer Drugs, Vol. 22, Núm. 1, pp. 1-8

2010

  1. Metástasis testicular de un adenocarcinoma de colon: Reporte de un caso

    Revista Venezolana de Oncologia, Vol. 22, Núm. 2, pp. 123-125

2009

  1. Bone lesions simulating multiple myeloma: Unusual presentation of esophageal cancer

    European Journal of Internal Medicine